Psilocybin Eating Disorder Treatment: Early Evidence and Cautions

Why Eating Disorders Are So Hard to Treat

Anorexia nervosa has one of the highest mortality rates of any psychiatric condition. Bulimia nervosa and binge eating disorder cause serious, lasting harm to physical and psychological health. And yet the treatment landscape for these conditions remains strikingly thin. Fluoxetine is the only pharmacological treatment currently approved for bulimia nervosa. No medications are FDA-approved for anorexia nervosa. Cognitive behavioral therapy helps a portion of patients, but relapse rates are high and many people never achieve lasting recovery.

What makes eating disorders so resistant to treatment is, in part, a matter of how they work at the neurological level. Cognitive inflexibility is a defining feature of these conditions. People with anorexia often describe their relationship to food, weight, and body image as something that feels less like a choice and more like a locked door. The thinking becomes rigid, repetitive, and difficult to interrupt regardless of how much distress it causes. Standard talk therapies can help people understand the patterns, but breaking them is another matter.

This is where researchers began looking at serotonergic psychedelics, particularly psilocybin, as a potential tool. Not because it is a cure, and not because the evidence is conclusive. Because the mechanism makes biological sense, and early data has been cautiously encouraging.

The Serotonin Connection

Eating disorders are associated with significant dysregulation of the serotonin system, specifically involving the 5-HT2A receptor. Serotonin influences mood, impulse control, and the flexibility with which the brain processes new information. In people with anorexia nervosa, altered serotonergic signaling appears to contribute to the cognitive rigidity and anxiety that drive the disorder. Bulimia nervosa involves a related but distinct pattern, with impulsive behavior and compulsive cycles of restriction and binge eating connected to similar neurochemical disruptions.

Psilocybin is a 5-HT2A receptor agonist. When it binds to those receptors, it temporarily disrupts habitual patterns of neural activity, particularly in the default mode network, the brain system associated with self-referential thought, rumination, and rigid identity. Neuroimaging research shows that psilocybin reduces activity in this network while increasing connectivity across other brain regions. In practical terms, this appears to create a window of increased cognitive and emotional flexibility, a loosening of entrenched patterns that are otherwise very hard to shift.

Whether that mechanism can be usefully applied to eating disorder treatment is the central question the field is now attempting to answer.

What the Clinical Research Shows So Far

The evidence base is small but growing. Two clinical studies have now been completed with eating disorder populations, and several more are actively recruiting.

The most significant study to date was a Phase 1 open-label feasibility trial published in Nature Medicine in 2023, conducted by researchers at the University of California, San Diego. Ten adult women with anorexia nervosa received a single 25mg synthetic psilocybin dose alongside psychological support. The primary aim was not to test efficacy but to assess safety and tolerability. The results were cautiously positive: no clinically significant changes in cardiac measures, vital signs, or laboratory values, and no serious adverse events. A subset of participants reported meaningful psychological shifts, including changes in their relationship to food, body image, and the psychological symptoms underlying the disorder. The researchers were careful to describe these findings as preliminary and inconclusive given the small sample and absence of a control group.

A second study, a 2026 open-label pilot published in the Journal of Eating Disorders, examined psilocybin-assisted therapy for binge eating disorder in five adults. All participants reported fewer binge eating episodes following treatment, with improvements sustained through three months of follow-up. Participants also reported reductions in depression and anxiety, and greater capacity to respond flexibly to difficult thoughts and emotions. The sample is too small to draw conclusions, but the safety profile was clean and the directional findings are consistent with the proposed mechanism.

Preclinical research adds another layer of biological plausibility. A 2024 study published in Molecular Psychiatry found that psilocybin reduced activity-based anorexia behaviors in female rats by enhancing cognitive flexibility through 5-HT1A and 5-HT2A receptor mechanisms. Animal models have obvious limitations when it comes to eating disorders, but findings like these help researchers understand why psilocybin might work, not just whether it does.

On the clinical trial registry, the picture is expanding. A UCSF trial (NCT06399263) opened in late 2024 and is actively recruiting young adults with anorexia, with a projected completion date of 2029. The Imperial College London study (NCT04505189) enrolled females with long-standing treatment-resistant anorexia across multiple psilocybin sessions, concluding in mid-2024. Results from that study are expected to add important data to the field.

The Cautions Are Real

Interest in this research area needs to be matched with serious caution, and researchers working in this space have been consistent on that point.

Eating disorders involve complex relationships between body image, identity, trauma, and control. In some cases, an altered-state experience could surface or intensify distressing material in ways that require careful clinical management. The psychological preparation and integration work surrounding a psilocybin session matter as much as the session itself. This is not a compound you take at home on a difficult Tuesday. The research protocols that have shown safety have done so in the context of structured clinical settings with trained guides, careful screening, and dedicated support before and after the session.

There is also the question of medical risk. People with severe anorexia nervosa may have cardiac vulnerabilities, electrolyte imbalances, and compromised physiological resilience that make any psychoactive intervention more complex to manage safely. The Phase 1 UCSD trial specifically enrolled participants with a mean BMI in the low-normal range; what the safety profile looks like for individuals with significantly lower BMI is not yet known. A systematic review published in 2025 in Eating and Weight Disorders identified only two studies meeting inclusion criteria for formal analysis, underscoring how early the field still is.

None of this means the research should not proceed. It means it needs to proceed carefully, which is exactly what it appears to be doing.

Why This Research Matters Regardless of Outcome

The honest answer about where psilocybin eating disorder treatment stands right now is: promising mechanism, early safety signal, insufficient efficacy data. That is a reasonable place to be for a field in Phase 1. What matters is that researchers are taking the question seriously, designing rigorous studies, and being transparent about what the evidence does and does not yet support.

For people who have exhausted conventional treatment options, the absence of meaningful alternatives is not a neutral condition. It carries real costs in suffering, in years lost to the illness, in lives that did not have to go the way they went. That context does not justify overstating the evidence. But it does justify continuing to look.

If larger, controlled trials replicate the early safety findings and show clinically meaningful symptom improvement, psilocybin-assisted therapy could eventually become one tool in a treatment system that currently has too few of them. The key phrase is “one tool.” In combination with skilled psychological support, careful screening, and a structured care framework, this approach may have a role. The research is asking whether that is true. We do not yet know the answer, and anyone who tells you otherwise is getting ahead of the data.

What It Would Look Like in Practice

If and when psilocybin-assisted therapy becomes an available option for eating disorders, it will not look like a standalone treatment. Every completed and registered study in this area uses psilocybin as an adjunct to structured psychotherapy, with preparation sessions beforehand and integration sessions afterward to help participants make sense of what arose during the experience and apply it meaningfully to their lives.

The guide relationship matters here as much as anywhere in psychedelic-assisted care, perhaps more so given the particular psychological vulnerabilities involved. Someone working through decades of disordered eating, distorted body image, and complex trauma around food needs a professional who understands both the psychedelic context and the specific clinical terrain of eating disorder treatment. That combination of expertise is rare, and building it will take time. The research is running ahead of the clinical infrastructure in some respects, which is a challenge the field will need to address as evidence accumulates.

For now, what this research offers is not a treatment, but a reason to keep looking at a question that genuinely needs better answers.